Chiesi Wins EU Nod For COPD Triple Combo, But Partner Is Predicted For Launch
Chiesi's triple combination therapy for COPD, Trimbow, has secured its first approval globally after winning a positive recommendation from the CHMP for its use in Europe – but analysts expect a respiratory partner will be required to launch the product.
You may also be interested in...
Ahead of a regulatory verdict in the US, GSK's triple combination therapy for COPD, Trelegy Ellipta, has won a positive recommendation in Europe.
There has been some criticism of the recent update to COPD management guidelines published by GOLD, with concern over the how much of the changes are based on clinical evidence.
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.